AstraZeneca (Switzerland)
- World rank, 2022–2025
- #16,620 of 28,054 · #31,234 all time
- Rank in Switzerland
- #111 of 220
- Research works
- 150 ▲ 105% vs 2013–17
- Citations
- 1.6k 10.6 per fractional work
- Top-10% rate
- 17.8% record average 16.5%
- Open access
- 56% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 4.8×. Every wedge is a field page.
- Immunology and Microbiology 4.8×
- Medicine 3.4×
- Biochemistry, Genetics and Molecular Biology 2.0×
- Pharmacology, Toxicology and Pharmaceutics 1.3×
- Economics, Econometrics and Finance 1.3×
- Mathematics 1.1×
- Health Professions 1.1×
- Decision Sciences 0.7×
- Nursing 0.7×
- Chemistry 0.7×
- Agricultural and Biological Sciences 0.4×
- Environmental Science 0.2×
- Earth and Planetary Sciences 0.2×
- Neuroscience 0.2×
- Computer Science 0.2×
- Social Sciences 0.1×
- Engineering 0.1×
- Psychology 0.1×
- Physics and Astronomy 0.0×
- Materials Science 0.0×
- Business, Management and Accounting 0.0×
Which keywords describe research at AstraZeneca (Switzerland)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Treatment, Epidemiology, Diagnosis, Inflammation, Management, Genetics, Asthma and Immunology.
- Treatment Guidelines
- Genomic Profiling
- Chronic Cough
- Monoclonal Antibodies
- Clinical Guidelines
- Inflammatory Diseases
- Adults
- Heart Failure
- Radiotherapy
- Guidelines
- Chemotherapy
- Clinical Trials
- Quality of Life
- spirometry
- Respiratory
- Eosinophils
- Immunology
- Genetics
- Diagnosis
- Treatment
- Epidemiology
- Inflammation
- Management
- Asthma
- Allergic Diseases
- Global Burden
- COPD
- Cardiovascular Disease
- Autoantibodies
- Precision Medicine
- Chronic Kidney Disease
- Fibrosis
- Children
- Targeted Therapy
- Eosinophilic Esophagitis
- TGF-ß
- Inhaler Devices
- Pulmonary Drug Delivery
- Cough Reflex Sensitivity
- Toll-like Receptors
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology12▲ 3.9×30 topics
- Treatment10▲ 11×16 topics
- Inflammation9▲ 5.2×33 topics
- Diagnosis8▲ 11×16 topics
- Management7▲ 11×10 topics
- Genetics6▲ 12×4 topics
- Asthma6▲ 77×2 topics
- Immunology6▲ 68×2 topics
- Allergic Diseases5▲ 116×1 topic
- Eosinophils5▲ 116×1 topic
- Global Burden5▲ 13×3 topics
- Respiratory4▲ 53×2 topics
- COPD4▲ 76×1 topic
- spirometry4▲ 76×1 topic
- Cardiovascular Disease3▲ 3.7×15 topics
- Quality of Life3▲ 2.9×12 topics
- Autoantibodies3▲ 16×6 topics
- Clinical Trials3▲ 5.2×9 topics
- Precision Medicine3▲ 7.4×7 topics
- Chemotherapy3▲ 4.6×11 topics
- Chronic Kidney Disease3▲ 13×7 topics
- Guidelines3▲ 7.1×6 topics
- Fibrosis2▲ 17×5 topics
- Radiotherapy2▲ 7.1×5 topics
- Children2▲ 11×3 topics
- Heart Failure2▲ 5.8×9 topics
- Targeted Therapy2▲ 11×3 topics
- Adults2▲ 38×1 topic
- Eosinophilic Esophagitis2▲ 89×1 topic
- Inflammatory Diseases2▲ 12×4 topics
- TGF-ß2▲ 14×4 topics
- Clinical Guidelines2▲ 7.4×5 topics
- Inhaler Devices2▲ 89×1 topic
- Monoclonal Antibodies2▲ 24×3 topics
- Pulmonary Drug Delivery2▲ 89×1 topic
- Chronic Cough2▲ 81×1 topic
- Cough Reflex Sensitivity2▲ 81×1 topic
- Genomic Profiling2▲ 20×2 topics
- Toll-like Receptors2▲ 18×2 topics
- Treatment Guidelines2▲ 9.5×3 topics
Which research topics does AstraZeneca (Switzerland) publish most on?
By volume in 2022–2025: Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, Eosinophilic Esophagitis and Inhalation and Respiratory Drug Delivery.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Asthma and respiratory diseases Physiology 5 works
- 2 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 4 works
- 3 Eosinophilic Esophagitis Surgery 2 works
- 4 Inhalation and Respiratory Drug Delivery Pulmonary and Respiratory Medicine 2 works
- 5 Respiratory and Cough-Related Research Pulmonary and Respiratory Medicine 2 works
- 6 Systemic Lupus Erythematosus Research Rheumatology 1 works
- 7 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 8 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 9 Chronic Kidney Disease and Diabetes Nephrology 1 works
- 10 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has AstraZeneca (Switzerland)'s research output changed?
Output in 2018–2022 was 105% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Zug
- Varian Medical Systems (Switzerland)
- Biogen (Switzerland)
- University of Teacher Education Zug
- Amgen (Switzerland)
- RHI Magnesita (Switzerland)
- Johnson & Johnson (Switzerland)
- SHL Medical (Switzerland)
- Sucampo (Switzerland)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.